VIDA Announces Series C Financing To Accelerate Access To AI-Powered Lung Imaging Analysis

CORALVILLE, Iowa, March 12, 2020 /PRNewswire/ — VIDA Diagnostics, Inc. (“VIDA”), the leader in AI-powered lung imaging analysis, today announced an $11M initial close of its Series C financing. The investment was led by First Analysis Corporation with initial equity participation from Blue Heron Capital and UnityPoint Health Ventures.  Existing investors including Next Level Ventures, Chartline Capital Partners, Rural Vitality Fund, Rittenhouse Ventures, Iowa First Capital Fund, and The Angels’ Forum also participated. VIDA will use the funds to address market deficits in the early assessment, monitoring, and treatment of lung disease by accelerating the commercialization of its leading LungPrint^® solution suite and by expanding LungPrint’s clinical portfolio.

“We are driven to continuously raise the standard of care for patients with or at risk of lung disease.  By equipping care teams with LungPrint, patient care and quality of life can be positively affected,” said Susan A. Wood, Ph.D. and CEO for VIDA.  “VIDA is endlessly thankful for the extensive support of the people, resources, and programs from the State of Iowa leading to this expansive funding.  VIDA can now accelerate LungPrint’s market access, further connecting its benefits to the many millions of patients with lung disease.”

“VIDA is an outstanding corporate citizen. The company’s commitment of employing and training Iowa-based engineers and scientists not only contributes to our economic growth, but also reinforces our skilled, productive workforce. The State of Iowa is proud of VIDA’s accomplishments, its worldwide recognition and to be a partner with them through robust economic development programs,” said Iowa Governor Kim Reynolds.  

Lung disease impacts over 500 million people globally¹, yet access to precise, personalized information for early detection and optimal treatment planning is not readily available.  The development of AI (Artificial Intelligence) – driven lung analysis, like VIDA’s LungPrint helps advance the standard of lung care by uniquely evaluating patients with or at risk of lung diseases, including emphysema and airway obstructive diseases (COPD), asthma, interstitial lung disease, and lung cancer.  Using a chest CT scan, functional and other patient data as input, LungPrint provides care teams with a rich set of precise quantitative insights useful at all points in the care path, from detection through treatment. 

Expanded volume and complexity of information contributes increasingly to radiologist task overload and burnout.  Chest CT scans are particularly tedious to interpret due to the extensive and complex search field.  LungPrint improves radiology efficiency by AI-driven automation and visualization paradigms, and quality evaluations.  VIDA is well positioned to address physician overload and burnout through a cadre of industry leading distribution partners, including Blackford, IBM Watson Health, Nuance Healthcare and TeraRecon, through the enhanced integration of LungPrint into the radiology workflow enabling diagnostic accuracy and workflow efficiency.

“VIDA is in an optimal position to serve a severely under-nourished area of the market where demand is high and supply is low,” said Tracy Marshbanks, Managing Director and General Partner at First Analysis.  “This investment will enable VIDA to meet the growing call for precise AI-driven lung analysis solutions that can help improve the quality of diagnosis and life for patients impacted by lung disease.”

About VIDA
VIDA provides the new standard of pulmonary care by using AI-powered CT imaging software and services to aid the early detection, evaluation, and treatment planning of patients with or at risk of lung diseases, including emphysema and airway obstructive diseases (COPD), asthma, interstitial lung disease, and lung cancer.  VIDA’s software and services are FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada and Australia.  More at vidalung.ai.

About First Analysis 
First Analysis is a leading venture capital investor, having invested more than $800 million over four decades.  With our integrative research process, we aim to invest in the best, established rapid-growth companies in the targeted sectors where we are acknowledged experts and where our success benefits not only our investors, but also our broader society and environment.  The integrative research process combines 1) dynamic investment research on thousands of publicly traded and privately held companies with 2) thousands of relationships among executives, investors, and other key participants in our focus areas, yielding a deep, comprehensive understanding of each sector’s near-term and long-term potential.  We help companies become profitable leaders in large markets, funding growth plans, working closely with management in areas including strategy, recruitment, sales and marketing, and corporate development, and typically investing $3-10 million as lead investor or as a syndicate partner who brings valuable perspective.

About Blue Heron Capital 
Blue Heron Capital is an operationally focused private investment firm based in Richmond, Virginia. The firm invests in small-cap growth equity companies in the healthcare and tech-enabled business services sectors.  Blue Heron supports portfolio companies with a team of industry experts, including C-level executives and successful entrepreneurs with decades of experience building and managing vibrant businesses.

About UnityPoint Health Ventures
Founded in 2019, UnityPoint Health Ventures makes direct investments in ideas and partners that provide an easier, more personal experience for patients and providers. As the venture capital arm of UnityPoint Health – one of the nation’s most integrated health systems – the firm invests in opportunities that improve patient outcomes and reduce the cost of health care. In addition to strategic investing, UnityPoint Health Ventures provides dedicated resources to accelerate portfolio company traction within UnityPoint Health and beyond. Through relationships with more than 315 physician clinics, 21 regional and 19 community network hospitals in metropolitan and rural communities and home care services throughout its 9 regions, UnityPoint Health provides care throughout Iowa, western Illinois and southern Wisconsin. More at uphventures.org.

¹ World Health Organization (link)

View original content to download multimedia:http://www.prnewswire.com/news-releases/vida-announces-series-c-financing-to-accelerate-access-to-ai-powered-lung-imaging-analysis-301022352.html

SOURCE VIDA Diagnostics, Inc.